Medical treatment of hepatocellular carcinoma.

摘要: Hepatocellular carcinoma is a rapidly fatal disease in most patients. In addition, many patients have underlying liver complicating their treatment. Prognostic factors been found that identify subset of who could benefit from therapy; though to date, chemotherapy, administered either intravenously or intra-arterially, has not altered the survival advanced recurrent disease. Patients with unfavorable prognostic factors, such as poor performance status, jaundice, overt failure, should be offered only supportive care. Treatment intravenous doxorubicin may considered better risk outside clinical trial, although it limited activity (less than 20 per cent response rate). Good status placed trials exploring both new ways deliver therapy and promising drugs.